Cue Biopharma, Inc. Increase (Decrease) in Accounts Receivable
Cue Biopharma, Inc. (CUE) reported Increase (Decrease) in Accounts Receivable of -$169.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-14
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $26.00K, a 95.11% decline year-over-year.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$195.00K.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $5.16M.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$145.00K, a 111.11% decline year-over-year.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $4.60M.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$753.00K, a 145.89% decline from fiscal 2023.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $1.64M.
- Cue Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$3.08M, a 278.84% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$169.00K 10-Q · filed 2026-08-14 | $4.99M derived: sum of 3 quarters · filed 2026-08-14 | $4.84M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$195.00K 10-Q · filed 2026-05-14 | $4.96M derived: sum of 2 quarters · filed 2026-05-14 | $4.82M derived: sum of 3 quarters · filed 2026-05-14 | $5.35M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.01M derived: sum of 2 quarters · filed 2026-03-16 | $5.55M derived: sum of 3 quarters · filed 2026-08-14 | $4.60M 10-K · filed 2026-03-16 | |
| 2025-09-30 | -$145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $387.00K derived: sum of 2 quarters · filed 2026-08-14 | -$558.00K 10-Q · filed 2025-11-12 | -$2.77M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$413.00K 10-Q · filed 2026-08-14 | -$2.62M derived: sum of 3 quarters · filed 2026-08-14 | -$1.31M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$945.00K 10-Q · filed 2026-05-14 | -$3.15M derived: sum of 2 quarters · filed 2026-05-14 | -$1.85M derived: sum of 3 quarters · filed 2026-05-14 | -$1.40M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$902.00K derived: sum of 2 quarters · filed 2026-03-16 | -$455.00K derived: sum of 3 quarters · filed 2026-03-16 | -$753.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.75M derived: sum of 2 quarters · filed 2025-11-12 | $1.45M 10-Q · filed 2025-11-12 | $1.49M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $149.00K 10-Q · filed 2025-08-12 | $187.00K derived: sum of 3 quarters · filed 2025-08-12 | $713.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$298.00K 10-Q · filed 2025-05-12 | -$260.00K derived: sum of 2 quarters · filed 2025-05-12 | $266.00K derived: sum of 3 quarters · filed 2025-05-12 | $1.20M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $564.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.50M derived: sum of 3 quarters · filed 2025-03-31 | $1.64M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $526.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.46M derived: sum of 2 quarters · filed 2024-11-14 | $1.60M 10-Q · filed 2024-11-14 | $865.00K derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $938.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.08M 10-Q · filed 2024-08-14 | $339.00K derived: sum of 3 quarters · filed 2024-08-14 | $399.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $139.00K 10-Q · filed 2024-05-09 | -$599.00K derived: sum of 2 quarters · filed 2024-05-09 | -$539.00K derived: sum of 3 quarters · filed 2024-05-09 | -$728.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$678.00K derived: sum of 2 quarters · filed 2024-03-28 | -$867.00K derived: sum of 3 quarters · filed 2024-03-28 | -$3.08M 10-K · filed 2024-03-28 | -$3.09M 10-K · filed 2023-03-21 |
| 2022-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$129.00K derived: sum of 2 quarters · filed 2023-11-03 | -$2.35M 10-Q · filed 2023-11-03 | $24.05K derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | -$189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.41M 10-Q · filed 2023-08-08 | -$35.95K derived: sum of 3 quarters · filed 2023-08-08 | -$1.17M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$2.22M 10-Q · filed 2023-05-09 | $153.04K derived: sum of 2 quarters · filed 2023-05-09 | -$979.96K derived: sum of 3 quarters · filed 2023-05-09 | -$488.95K derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $1.24M derived: sum of 2 quarters · filed 2023-03-21 | $1.73M derived: sum of 3 quarters · filed 2023-03-21 | $1.73M 10-K · filed 2023-03-21 | |
| 2021-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$642.00K derived: sum of 2 quarters · filed 2022-11-14 | -$646.00K 10-Q · filed 2022-11-14 | $314.58K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $491.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $487.00K 10-Q · filed 2022-08-04 | $1.45M derived: sum of 3 quarters · filed 2022-08-04 | $676.58K derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$4.00K 10-Q · filed 2022-05-10 | $956.58K derived: sum of 2 quarters · filed 2022-05-10 | $185.58K derived: sum of 3 quarters · filed 2022-05-10 | $808.58K derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $960.58K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $189.58K derived: sum of 2 quarters · filed 2022-03-16 | $812.58K derived: sum of 3 quarters · filed 2022-03-16 | $662.58K 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$771.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$148.00K derived: sum of 2 quarters · filed 2021-11-09 | -$298.00K 10-Q · filed 2021-11-09 | -$153.10K derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $623.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $473.00K 10-Q · filed 2021-08-09 | $617.90K derived: sum of 3 quarters · filed 2021-08-09 | $705.90K derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | -$150.00K 10-Q · filed 2021-05-10 | -$5.10K derived: sum of 2 quarters · filed 2021-05-10 | $82.90K derived: sum of 3 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $144.90K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $232.90K derived: sum of 2 quarters · filed 2021-03-09 | $754.90K 10-K · filed 2021-03-09 | ||
| 2019-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $610.00K 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $522.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |